Ocular Therapeutix (NASDAQ: OCUL) is one of 80 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its rivals? We will compare Ocular Therapeutix to similar businesses based on the strength of its institutional ownership, earnings, analyst recommendations, valuation, dividends, profitability and risk.
Institutional and Insider Ownership
52.4% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 67.2% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 26.1% of Ocular Therapeutix shares are owned by company insiders. Comparatively, 11.7% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Ocular Therapeutix and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ocular Therapeutix Competitors||-125.29%||-43.73%||-11.32%|
Volatility and Risk
Ocular Therapeutix has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Ocular Therapeutix’s rivals have a beta of 1.10, suggesting that their average stock price is 10% more volatile than the S&P 500.
This is a summary of current ratings and price targets for Ocular Therapeutix and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ocular Therapeutix Competitors||205||1198||2673||86||2.63|
Ocular Therapeutix presently has a consensus target price of $22.29, suggesting a potential upside of 318.90%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 6.86%. Given Ocular Therapeutix’s stronger consensus rating and higher possible upside, research analysts clearly believe Ocular Therapeutix is more favorable than its rivals.
Valuation & Earnings
This table compares Ocular Therapeutix and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Ocular Therapeutix||$1.89 million||-$44.70 million||-2.33|
|Ocular Therapeutix Competitors||$1.03 billion||$127.56 million||215.12|
Ocular Therapeutix’s rivals have higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Ocular Therapeutix rivals beat Ocular Therapeutix on 7 of the 12 factors compared.
About Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.
Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.